Skip to main content
OpenTrials
Completed

NCT Number: NCT04646993

WHITE Study: WHIch Decision After a First Venous ThromboEmbolism?

The WHITE study is a multicenter, multinational, investigators-initiated, observational, prospective study conducted in a consecutive series of ambulatory patients who had completed the recommended or practicable period of anticoagulation after a first-ever episode of venous thromboembolism (VTE)

The general aim of the study is to evaluate the distribution of decisions and of the reasons guiding the physician's decision on the modality to manage the secondary prevention of VTE in patients treated for a first-ever episode of VTE, after the initial 3-12 months of anticoagulant therapy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Clinical Trial Centre, MATMED

Hodonín, 695 01, Czechia

About this study

The WHITE study is an international, non-profit, multicenter, observational, prospective and no profit study 3,200 subjects having experienced a first-ever episode of DVT of the lower limbs and/or PE, receive anticoagulation therapy for a period as recommended by international and/or local practice guidelines will be enrolled across all the countries participating to the study.

When this recommended period expires, the attending physician has to decide whether to continue with anticoagulation, switch to anti-thrombotic of another class, or stop any prophylactic pharmacological treatment.

The primary objective of the study is the evaluation of the distribution of decisions and of the reasons guiding the physician's decision on the modality to manage the secondary prevention of VTE in patients treated for a first-ever episode of VTE, after the initial 3-12 months of anticoagulation therapy.

The secondary objective is the collection of data during the follow-up: the frequency of thromboembolic complications, of bleeding complications, or death from any cause.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • subjects who provided a written informed consent and authorization for disclosure of protected health information;
  • male and female adult or elderly patients of any ethnicity having had a first-ever event of provoked or unprovoked DVT of the lower limbs and/or PE and treated with oral anticoagulant
  • for whom the center is in possession of all the data relevant to the index event;
  • having a permanent reference contact.

Exclusion criteria

  • subjects <18 years old;
  • subjects unable or unwilling to issue the written informed consent;
  • subjects for whom the information relevant to the index event are incomplete or inaccessible to the Investigator;
  • subject in whom the index event was a DVT not of the lower limbs;
  • subjects with life expectancy of less than 2 years;
  • subjects participating in any other clinical study, regardless of its nature;
  • subjects considered, by the attending physician, unable to comply with the study procedures.

Treatment and study plan

Primary outcomes

  1. Number of patients who continue or stop the anticoagulant treatment

    Time frame: From the end of the 3rd month to the end of 12th month of anticoagulant treatment

    Registration of number of patients who continue or stop the treatment; registration of type reasons guiding the attending physician's decision on the management of secondary prevention (eg: Bleeding score, laboratory test, presence of residual vein trombosis, risk or recurrence)

Secondary outcomes

  1. Frequence of adverse events during follow-up

    Time frame: Frome the first day of enrollment up to 24 monhts

    the frequency of thromboembolic complications, of bleeding complications, or death from any cause monitored during the follow-up.

Sponsors and collaborators

Lead sponsor

Arianna Anticoagulazione Foundation

Other

Registry information

Official study title

Which Decision After a First Venous Thromboembolism? The WHITE Study

Acronym: WHITE

Important dates

Study start
2018
Primary completion
2021
Study completion
2022
First posted
Nov 30, 2020
Registry last updated
Mar 11, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.